Evidence map›Paper›PMID 25036702›Full record

ArticleThe Journal of clinical investigation2014

Wetting the whistle: neurotropic factor improves salivary function.

Adam Swick, Randall J Kimple

Abstract readComment
In one paragraph

Article in The Journal of clinical investigation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Adam Swick
Randall J Kimple

Funding

Head and Neck squamous cell carcinoma radiation response modulation by HPVR00CA160639 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KIMPLE, RANDALL J. · 2013 to 2015
$725k
Head and Neck squamous cell carcinoma radiation response modulation by HPVK99CA160639 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KIMPLE, RANDALL J. · 2011 to 2012
$298k
NCI NIH HHS CA160639NCI NIH HHS K99 CA160639NCI NIH HHS R00 CA160639
6 · The paper itself

Abstract

Xerostomia, or dry mouth, is a common side effect of head and neck radiotherapy, Sjögren syndrome, diabetes, old age, and numerous medications. In this issue of the JCI, Xiao and colleagues identified glial cell line-derived neurotrophic factor (GDNF) as a potential stimulus for salivary stem cell growth. Due to its ability to promote neuronal growth, differentiation, and survival, GDNF is currently being used in clinical trials as a treatment for Parkinson disease; therefore, the findings of Xiao and colleagues may initiate a potential treatment for the millions of patients who suffer from xerostomia each year.

Indexed as

Adult Stem CellsAnimalsFemaleGlial Cell Line-Derived Neurotrophic FactorHumansMaleSalivary GlandsGDNF protein, humanGdnf protein, mouseGlial Cell Line-Derived Neurotrophic Factor

Identifiers

PMID25036702
PMCPMC4109536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.